Showing 1 posts of 1 posts found.
Reports of adverse drug events submitted to the FDA by pharma firms are often incomplete and lacking in detail, a …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement